| Functional genome analysis of Bifidobacterium breve UCC2003 reveals type IVb tight adherence (Tad) pili as an essential and conserved host-colonization factor M O'Connell Motherway, A Zomer, SC Leahy, J Reunanen, F Bottacini, ... Proceedings of the National Academy of Sciences 108 (27), 11217-11222, 2011 | 431 | 2011 |
| IL-1 family members in cancer; two sides to every story KJ Baker, A Houston, E Brint Frontiers in immunology 10, 459981, 2019 | 255 | 2019 |
| Immune privilege or inflammation? Insights into the Fas ligand enigma. J O'Connell, A Houston, MW Bennett, GC O'Sullivan, F Shanahan Nature medicine 7 (3), 271-274, 2001 | 200 | 2001 |
| The Fas signalling pathway and its role in the pathogenesis of cancer A Houston, J O’Connell Current opinion in pharmacology 4 (4), 321-326, 2004 | 179 | 2004 |
| Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? G O'callaghan, A Houston British journal of pharmacology 172 (22), 5239-5250, 2015 | 172 | 2015 |
| Identification of TLR10 as a key mediator of the inflammatory response to Listeria monocytogenes in intestinal epithelial cells and macrophages T Regan, K Nally, R Carmody, A Houston, F Shanahan, J MacSharry, ... The Journal of Immunology 191 (12), 6084-6092, 2013 | 166 | 2013 |
| Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor‐immune conflict JOE O'CONNELL, MW Bennett, K Nally, A Houston, GC O'SULLIVAN, ... Annals of the New York Academy of Sciences 910 (1), 178-195, 2000 | 165 | 2000 |
| Addressing the “Fas counterattack” controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo AE Ryan, F Shanahan, J O'Connell, AM Houston Cancer research 65 (21), 9817-9823, 2005 | 114 | 2005 |
| An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer C O'donnell, A Mahmoud, J Keane, C Murphy, D White, S Carey, ... British journal of cancer 114 (1), 37-43, 2016 | 90 | 2016 |
| Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn's disease: a role for Tollip and peroxisome proliferator-activated receptor gamma? P Fernandes, J MacSharry, T Darby, A Fanning, F Shanahan, A Houston, ... Clinical & Experimental Immunology 183 (3), 358-368, 2016 | 78 | 2016 |
| A bifidobacterial pilus‐associated protein promotes colonic epithelial proliferation M O'Connell Motherway, A Houston, G O’Callaghan, J Reunanen, ... Molecular microbiology 111 (1), 287-301, 2019 | 72 | 2019 |
| Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-β expression A Houston, MW Bennett, GC O'Sullivan, F Shanahan, J O'Connell British journal of cancer 89 (7), 1345-1351, 2003 | 72 | 2003 |
| Life in the Fas lane: differential outcomes of Fas signaling E Brint, G O’Callaghan, A Houston Cellular and molecular life sciences 70, 4085-4099, 2013 | 70 | 2013 |
| Fas ligand upregulation is an early event in colonic carcinogenesis MW Bennett, J O'Connell, A Houston, J Kelly, GC O'Sullivan, JK Collins, ... Journal of clinical pathology 54 (8), 598-604, 2001 | 67 | 2001 |
| Mesenchymal stromal cells (MSCs) and colorectal cancer - a troublesome twosome for the anti-tumour immune response? ELJRAE O'Malley G, Heijltjes M, Houston AM, Rani S, Ritter T Oncotarget, 2016 | 64* | 2016 |
| Modulation of p21‐activated kinase 1 alters the behavior of renal cell carcinoma GC O'Sullivan, M Tangney, G Casey, M Ambrose, A Houston, OP Barry International journal of cancer 121 (9), 1930-1940, 2007 | 59 | 2007 |
| Fas ligand promotes tumor immune evasion of colon cancer in vivo AE Ryan, F Shanahan, J O’Connell, AM Houston Cell cycle 5 (3), 246-249, 2006 | 56 | 2006 |
| Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells G O'callaghan, J Kelly, F Shanahan, A Houston British journal of cancer 99 (3), 502-512, 2008 | 46 | 2008 |
| Selective influence of host microbiota on cAMP‐mediated ion transport in mouse colon KW Lomasney, A Houston, F Shanahan, TG Dinan, JF Cryan, NP Hyland Neurogastroenterology & Motility 26 (6), 887-890, 2014 | 44 | 2014 |
| Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo A Houston, FD Waldron‐Lynch, MW Bennett, D Roche, GC O'Sullivan, ... International journal of cancer 107 (2), 209-214, 2003 | 44 | 2003 |
